Celularity Inc. (CELU) is a Biotechnology company in the Healthcare sector, currently trading at $1.30. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is CELU = $3 (+130.8% upside).
Valuation: CELU trades at a trailing Price-to-Earnings (P/E) of -0.5 (S&P 500 average ~25).
Financials: revenue is $54M, +49.7%/yr average growth. Net income is $58M (loss), growing at -432.8%/yr. Net profit margin is -106.8% (negative). Gross margin is 83.6% (+28.8 pp trend).
Balance sheet: total debt is $29M against $9M equity (Debt-to-Equity (D/E) ratio 3.29, leveraged). Current ratio is 0.38 (tight liquidity). Debt-to-assets is 21.9%. Total assets: $133M.
Analyst outlook: 3 / 6 analysts rate CELU as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 0/100 (Fail), Moat 50/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).
